{"id":"NCT02322216","sponsor":"Alcon Research","briefTitle":"Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects","officialTitle":"A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2014-12-23","resultsPosted":"2016-10-12","lastUpdate":"2017-11-17"},"enrollment":383,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Olopatadine Hydrochloride Ophthalmic Solution 0.2%","otherNames":["PATADAY®"]},{"type":"DRUG","name":"Olopatadine Hydrochloride Ophthalmic Solution 0.1%","otherNames":["PATANOL®"]},{"type":"DRUG","name":"Olopatadine 0.2% Vehicle","otherNames":[]}],"arms":[{"label":"PATADAY","type":"EXPERIMENTAL"},{"label":"PATANOL","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.","primaryOutcome":{"measure":"Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14","timeFrame":"Baseline, Day 14","effectByArm":[{"arm":"PATADAY","deltaMin":-2.57,"sd":0.09},{"arm":"PATANOL","deltaMin":-2.62,"sd":0.092}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":383},"commonTop":[]}}